title: Improved perfusion after subcritical ischemia in muscle flaps treated with vascular endothelial growth factor.
abstract: Vascular endothelial growth factor (VEGF), a potent endothelial mitogen, is secreted in ischemic tissue and plays a pivotal role in angiogenesis. We studied whether VEGF administered to a rat muscle flap at the time of ischemia induction would increase microcirculatory flow to the flap. The cremaster muscle flap was isolated on its neurovascular pedicle. Ischemia was induced by clamping the vascular pedicle, and 0.2 ml of either VEGF (0.1 microg) or vehicle (phosphate-buffered saline) was immediately infused into the muscle. After 4 or 6 hours, the clamps were released, and the cremaster was placed in a pocket in the medial thigh for 24 hours. The muscle was then dissected, and microcirculatory measurements were made under intravital microscopy. Six animals were used in each of the four groups. All flaps exposed to 6 hours of ischemia, the duration considered to be critical ischemia, had no significant microcirculatory flow, regardless of treatment with VEGF. In the 4-hour ischemia group, or subcritical ischemia group, red blood cell velocity in arterioles was 14 mm/sec in muscles treated with VEGF and 9 mm/sec in controls (p = 0.02), and capillary flow was 7 per high-power field in muscles treated with VEGF versus 2 per high-power field in controls (p = 0.0005). Thus, VEGF did not alter microcirculatory flow in a muscle flap exposed to critical ischemia, but it did enhance flow to a flap exposed to subcritical ischemia.
authors: Department of Plastic and Reconstructive Surgery, Cleveland Clinic Foundation, Ohio 44195, USA. banburj@ccf.org
authors: J
authors: J
authors: Banbury
authors: M
authors: M
authors: Siemionow
authors: S
authors: S
authors: Porvasnik
authors: S
authors: S
authors: Petras
authors: E
authors: E
authors: Browne
mesh_terms: D000818:Animals; D001160:Arterioles / Q000187:drug effects; D001783:Blood Flow Velocity / Q000187:drug effects; D002196:Capillaries / Q000187:drug effects; D003250:Constriction; D004210:Dissection; D016228:Endothelial Growth Factors / Q000008:administration & dosage / Q000627:therapeutic use*; D004912:Erythrocytes / Q000187:drug effects; D007511:Ischemia / Q000503:physiopathology*; D008222:Lymphokines / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008833:Microcirculation / Q000187:drug effects; D008853:Microscopy; D018482:Muscle, Skeletal / Q000187:drug effects / Q000637:transplantation*; D014677:Pharmaceutical Vehicles; D020033:Protein Isoforms / Q000008:administration & dosage / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012039:Regional Blood Flow / Q000187:drug effects; D013524:Surgical Flaps / Q000098:blood supply*; D013997:Time Factors; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
chemical_list: D016228:Endothelial Growth Factors; D008222:Lymphokines; D014677:Pharmaceutical Vehicles; D020033:Protein Isoforms; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors